Generation Bio’s (GBIO) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Generation Bio (NASDAQ:GBIO) in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a $10.00 price target on the stock.

Separately, Wedbush restated an “outperform” rating and issued a $5.00 target price on shares of Generation Bio in a research report on Thursday, August 8th.

Generation Bio Trading Down 4.7 %

Shares of NASDAQ:GBIO opened at $2.22 on Wednesday. The firm has a 50 day moving average of $2.49 and a 200-day moving average of $2.83. The stock has a market capitalization of $147.69 million, a PE ratio of -0.91 and a beta of 2.80. Generation Bio has a 12 month low of $0.86 and a 12 month high of $4.65.

Generation Bio (NASDAQ:GBIO) last issued its earnings results on Wednesday, August 7th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The firm had revenue of $4.09 million during the quarter, compared to analyst estimates of $3.23 million. Generation Bio had a negative net margin of 1,202.56% and a negative return on equity of 92.86%. On average, research analysts predict that Generation Bio will post -1.8 EPS for the current fiscal year.

Hedge Funds Weigh In On Generation Bio

Institutional investors have recently added to or reduced their stakes in the stock. PFG Advisors acquired a new position in Generation Bio during the 1st quarter worth approximately $41,000. SG Americas Securities LLC acquired a new position in Generation Bio during the 3rd quarter worth approximately $42,000. Cubist Systematic Strategies LLC increased its position in Generation Bio by 91.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock worth $54,000 after purchasing an additional 9,075 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Generation Bio during the 1st quarter worth approximately $74,000. Finally, American Century Companies Inc. increased its position in Generation Bio by 199.3% during the 2nd quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock worth $90,000 after purchasing an additional 21,167 shares in the last quarter. 95.22% of the stock is currently owned by institutional investors and hedge funds.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.